Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter. (13:27)
Tag Archives: paclitaxel
TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin) for intermediate/poor risk germ cell tumors, with discussion of outcomes in patients with a p53 mutation. (3:39)
Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (BMIC-048)
Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (1:40)
T Effector Gene Signature on IMpower150: Is There a Better Biomarker than PD-L1 for Immunotherapy? (BMIC-021)
Dr. Jack West reviews provocative biomarker results on the IMpower150 trial that tested atezolizumab with carboplatin/paclitaxel +/- bevacizumab & revealed strongest benefit of atezo in those with T effector gene signature high expression or high PD-L1. (10:19)
Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020)
Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immune checkpoint inhibitor atezolizumab to carbo/paclitaxel/bevacizumab in patients with chemo-naïve advanced non-squamous NSCLC. (11:28)